Enveric Biosciences (ENVB) Other Non-Current Liabilities (2015 - 2023)
Enveric Biosciences (ENVB) posted Other Non-Current Liabilities of $714000.0 for Q2 2023, up 881381.48% sequentially from $81.0 in Q4 2022, and down 64.36% YoY from $2.0 million in Q2 2022.
Enveric Biosciences (ENVB) Other Non-Current Liabilities (2015 - 2023) Analysis & Trends
Enveric Biosciences has reported Other Non-Current Liabilities for 6 years, with the latest figure at $714000.0 in Q2 2023.
- Quarterly Other Non-Current Liabilities fell 64.36% year-over-year to $714000.0 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $714000.0 (down 64.36% YoY) and the FY2022 annual result came in at $81.0, down 99.99% from the prior year.
- Other Non-Current Liabilities rose to $714000.0 in Q2 2023 per ENVB's latest filing, from $81.0 in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $6.2 million in Q1 2021 and troughed at $81.0 in Q4 2022.
- A 4-year average of $2.7 million and a median of $3.2 million in 2021 frame the typical range for Other Non-Current Liabilities.
- The widest YoY moves for Other Non-Current Liabilities: up 35.58% in 2022, down 99.99% in 2022.
- Over 4 years, Other Non-Current Liabilities stood at $4.3 million in 2019, then plunged by 84.62% to $653674.0 in 2021, then tumbled by 99.99% to $81.0 in 2022, then soared by 881381.48% to $714000.0 in 2023.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $714000.0, $81.0, and $654937.0 for Q2 2023, Q4 2022, and Q3 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - |
| 10 | Enveric Biosciences | 5.58 Mn | -2.71 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 714,000.00 |
| Dec 31, 2022 | 81.00 |
| Sep 30, 2022 | 654,937.00 |
| Jun 30, 2022 | 2.00 Mn |
| Mar 31, 2022 | 3.97 Mn |
| Dec 31, 2021 | 653,674.00 |
| Sep 30, 2021 | 3.17 Mn |
| Jun 30, 2021 | 3.71 Mn |
| Mar 31, 2021 | 6.17 Mn |
| Jun 30, 2019 | 4.25 Mn |
| Mar 31, 2019 | 4.64 Mn |
| Dec 31, 2018 | 4.19 Mn |
| Sep 30, 2018 | 1.69 Mn |
| Sep 30, 2015 | 400,000.00 |